乳腺癌组织中低水平ERBB2蛋白表达的检测分析
该研究评估现行标准ERBB2免疫组化检测能否准确筛选低ERBB2阳性乳腺癌患者以接受德曲妥珠单抗(T-DXd)治疗。美国病理学家学会调查数据显示19%的病例在0与1+评分间一致率≤70%;18名病理学家阅读170例活检的4分制一致率在0与1+间仅26%,而2+与3+间为58%。作者认为低表达区评分准确性差,可能导致患者被错误分配治疗。
要点
- 美国病理学家学会调查中19%的病例在ERBB2 0与1+间一致率≤70%。
- 18名病理学家对0与1+的评分一致率仅26%,2+与3+间为58%。
- 现行标准ERBB2免疫组化在低表达区(0和1+)评分准确性差。
核心结论
- 使用现行标准ERBB2免疫组化检测,低表达区(0和1+)的评分准确性差,现实世界中可能导致许多患者被错误分配接受T-DXd治疗。
研究设计与样本
- 评估美国病理学家学会调查数据及耶鲁大学一项18名病理学家阅读170例乳腺活检一致性的分析数据。
- 调查数据集包含1391至1452家实验室在2年内对每家实验室40个ERBB2核心(每年20个核心两次,共80个)的评分。
主要发现
- 美国病理学家学会调查显示,实验室判读的病例中19%在ERBB2免疫组化评分0与1+间一致率≤70%。
- 18名病理学家以4分制阅读选定乳腺活检扫描切片时,0与1+间一致率仅26%,而2+与3+间一致率为58%。
关键数值与推荐
- 德曲妥珠单抗(T-DXd)在中心病理实验室判读ERBB2免疫组化评分为1+或2+(非0)的乳腺癌患者中显示疗效。
- 美国病理学家学会调查中,19%的病例在免疫组化ERBB2评分0与1+间一致率≤70%。
- 18名病理学家阅读时,0与1+间一致率为26%,2+与3+间一致率为58%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Trastuzumab deruxtecan (T-DXd) has shown efficacy in patients with breast cancer with ERBB2 immunohistochemistry (IHC) scores of 1+ or 2+ but not 0 as read in central pathology laboratories. The drug is currently being tested in large randomized clinical trials with registration intent for this patient population. OBJECTIVE: To determine the suitability of the current standard ERBB2 IHC assays to select patients with low ERBB2 positivity for treatment with T-DXd. DESIGN AND SETTING: Assessment of data from College of American Pathologists surveys and assessment of analytic data from a Yale University-based study of concordance of 18 pathologists reading 170 breast cancer biopsies. RESULTS: The total survey data set included scores over 2 years from 1391 to 1452 laboratories of 40 ERBB2 cores from each laboratory (20 cores twice a year for a total of 80). College of American Pathologists surveys show that 19% of cases read by the laboratories generate results with less than or equal to 70% concordance for IHC ERBB2 score 0 vs 1+. When 18 pathologists read the scanned slides from a selected set of breast cancer biopsies using a 4-point scale, there was only 26% concordance between 0 and 1+ compared with 58% concordance between 2+ and 3+. CONCLUSIONS AND RELEVANCE: In this study using a current standard ERBB2 IHC assay, the scoring accuracy for ERBB2 IHC in the low range (0 and 1+) was poor. This inaccuracy in the real world could lead to misassignment of many patients for treatment with T-DXd.
引用
- Fernandez AI, Liu M, Bellizzi A, et al. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncol. 2022. PMID: 35113160. doi:10.1001/jamaoncol.2021.7239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。